Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Study ID: Children's Oncology Group (COG) - AAML1531

Trial Title: Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Submitted in collaboration with the NCTN/NCORP Data Archive

Data presented in the following publication(s): 34320162

Disease type(s): Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia; Hematopoietic Neoplasm/Leukemia - Myelodysplastic Syndrome

Dataset(s) included:

NCT02521493-D1: There are 2 datasets associated with PMID 34320162, NCT02521493-D1 through NCT02521493-D2. The NCT02521493-D1 dataset is a patient level dataset (single row per patient) containing patient characteristics, laboratory findings, and outcome for eligible myeloid leukemia in children with Down syndrome (ML-DS) enrolled on the AAML1531 clinical trial.
NCT02521493-D2: There are 2 datasets associated with PMID 34320162, NCT02521493-D1 through NCT02521493-D2. The NCT02521493-D2 dataset is an adverse event level dataset (single row per adverse event, period, and patient) containing information of the micro-organisms associated with adverse events by period in the AAML1531 clinical trial.